The balance sheet remains conservatively leveraged with a debt-to-equity ratio of 0.06 and cash of $152.6M, though equity growth has slowed amid the client loss.
Progyny, Inc. (PGNY) balance sheet — 9-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Total Current Assets | 464.4M | 551.77M | 472.72M | 640.41M | 433.86M | 258.54M | 190.22M | 132.44M | 24.54M | 16.77M |
| Cash & Short-Term Investments | 195.59M | 310.1M | 227.95M | 371.09M | 189.3M | 119.42M | 109.3M | 80.38M | 127K | 4.69M |
| Cash Only | 116.82M | 112.24M | 162.31M | 97.3M | 120.08M | 91.41M | 70.31M | 80.38M | 127K | 4.69M |
| Short-Term Investments | 78.77M | 197.86M | 65.64M | 273.79M | 69.22M | 28M | 38.99M | 0 | 0 | 0 |
| Accounts Receivable | 249.18M | 220.29M | 235.32M | 241.87M | 240.07M | 134.56M | 75.66M | 47.06M | 23.32M | 11.37M |
| Days Sales Outstanding | 67.52 | 62.39 | 73.59 | 81.1 | 111.35 | 98.1 | 80.08 | 74.78 | 80.77 | 85.44 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 19.63M | 21.39M | 9.44M | 27.45M | 4.49M | 0 | 0 | 0 | 200K | 0 |
| Total Non-Current Assets | 211.39M | 190.66M | 134.38M | 116.21M | 109.13M | 99.53M | 63.7M | 17.99M | 16.79M | 18.19M |
| Property, Plant & Equipment | 73.12M | 54.92M | 29.63M | 27.82M | 15.27M | 12.83M | 12.07M | 3.08M | 776K | 597K |
| Fixed Asset Turnover | 23.28x | 23.47x | 39.39x | 39.13x | 51.52x | 39.01x | 28.58x | 74.50x | 135.82x | 81.38x |
| Goodwill | 19.83M | 19.98M | 15.53M | 11.88M | 11.88M | 11.88M | 11.88M | 11.88M | 11.88M | 11.88M |
| Intangible Assets | 5.53M | 6.22M | 1.3M | 0 | 99K | 599K | 1.21M | 2.38M | 3.86M | 5.34M |
| Long-Term Investments | 925K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 19.83M | 16.54M | 2.98M | 3.4M | 3.99M | 2.94M | 573K | 652K | 272K | 372K |
| Total Assets | 675.79M | 742.43M | 607.1M | 756.62M | 542.99M | 358.06M | 253.93M | 150.43M | 41.32M | 34.96M |
| Asset Turnover | 1.89x | 1.74x | 1.92x | 1.44x | 1.45x | 1.40x | 1.36x | 1.53x | 2.55x | 1.39x |
| Asset Growth % | -3.03% | 22.29% | -19.76% | 39.34% | 51.64% | 41.01% | 68.8% | 264.04% | 18.2% | - |
| Total Current Liabilities | 240.04M | 202.39M | 168.63M | 185.95M | 159.54M | 98.82M | 77.79M | 36.16M | 30.2M | 17.77M |
| Accounts Payable | 148M | 124.07M | 95.1M | 125.43M | 109.29M | 61.4M | 43.51M | 19.39M | 15.58M | 5.13M |
| Days Payables Outstanding | 52.8 | 46.01 | 37.98 | 53.87 | 64.38 | 57.69 | 57.8 | 38.42 | 66.14 | 45.47 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 253K | 3.56M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.39M | 7.13M |
| Other Current Liabilities | 0 | 23.48M | 19.87M | 13.05M | 8.88M | 12.26M | 7.69M | 13M | 11.64M | 6.73M |
| Current Ratio | 1.93x | 2.73x | 2.80x | 3.44x | 2.72x | 2.62x | 2.45x | 3.66x | 0.81x | 0.94x |
| Quick Ratio | 1.93x | 2.73x | 2.80x | 3.44x | 2.72x | 2.62x | 2.45x | 3.66x | 0.81x | 0.94x |
| Cash Conversion Cycle | 14.72 | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 21.73M | 24M | 16.41M | 17.24M | 6.48M | 7.42M | 9.19M | 0 | 106.24M | 6.5M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.63M |
| Capital Lease Obligations | 91.47M | 24M | 16.41M | 17.24M | 6.48M | 7.42M | 8.32M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 876K | 0 | 0 | 4.87M |
| Total Liabilities | 261.76M | 226.39M | 185.04M | 203.19M | 166.02M | 106.24M | 86.98M | 36.16M | 30.2M | 24.27M |
| Total Debt | 21.73M | 27.73M | 19.27M | 19.39M | 7.71M | 8.65M | 9.55M | 0 | 253K | 5.19M |
| Net Debt | -95.09M | -84.51M | -143.04M | -77.91M | -112.36M | -82.76M | -60.76M | -80.38M | 126K | 497K |
| Debt / Equity | 0.05x | 0.05x | 0.05x | 0.04x | 0.02x | 0.03x | 0.06x | - | 0.02x | 0.49x |
| Debt / EBITDA | 0.16x | 0.31x | 0.27x | 0.30x | 0.31x | 0.26x | 0.93x | - | - | - |
| Net Debt / EBITDA | -0.71x | -0.94x | -2.03x | -1.21x | -4.51x | -2.46x | -5.93x | -6.81x | - | - |
| Interest Coverage | - | - | - | - | - | - | - | 166.84x | -6.95x | -14.87x |
| Total Equity | 414.03M | 516.04M | 422.06M | 553.43M | 376.97M | 251.82M | 166.95M | 114.27M | 11.12M | 10.69M |
| Equity Growth % | -21.75% | 22.27% | -23.74% | 46.81% | 49.7% | 50.84% | 46.1% | 927.43% | 4.04% | - |
| Book Value per Share | 5.10 | 5.77 | 4.42 | 5.50 | 3.77 | 2.51 | 1.69 | 1.37 | 0.14 | 1.88 |
| Total Shareholders' Equity | 414.03M | 516.04M | 422.06M | 553.43M | 376.97M | 251.82M | 166.95M | 114.27M | 11.12M | 10.69M |
| Common Stock | 9K | 9K | 9K | 9K | 9K | 9K | 9K | 8K | 1K | 1K |
| Retained Earnings | 281.36M | 202.83M | 144.31M | 89.97M | 27.93M | -2.42M | -68.19M | -113.48M | -104.85M | -104.56M |
| Treasury Stock | -621.04M | -388.07M | -303.89M | -1.01M | -1.01M | -1.01M | -1.01M | -1.01M | -884K | 0 |
| Accumulated OCI | 173K | 498K | 39K | 2.82M | 501K | -93K | 1K | -150.43M | -483K | -83K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying PGNY stock.
As of 2025, Progyny, Inc. (PGNY) had total assets of $742.4M including $551.8M in current assets.
Progyny, Inc. (PGNY) carries total debt of $27.7M, offset by $310.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Progyny, Inc. (PGNY) has total shareholders' equity (book value) of $516.0M ($5.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Progyny, Inc. (PGNY) reported a current ratio of 2.73x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Client concentration and utilization volatility
Metrics are mathematically derived from official filings.
Equity Growth Slows Amid Client Loss
Total equity rose to $453.3M in Q2 2026 from $422.1M a year earlier, but the pace of growth decelerated sharply, reflecting the reported loss of a major enterprise client and a maturing revenue base.
The balance sheet is still expanding, but the rate of equity accumulation has slowed from 8.1% year-over-year in Q2 2025 to 7.4% in Q2 2026, per reported figures. This deceleration aligns with the revenue slowdown and suggests that the company's ability to generate retained earnings is being tested. Investors should monitor whether the equity growth can be sustained without the contribution from the lost client.
Minimal Leverage Masks Refinancing Risk
Total debt of $27.0M in Q2 2026 represents a debt-to-equity ratio of just 0.06, per financial statements, indicating minimal reliance on borrowed capital, but the slight increase in debt over the past year warrants monitoring.
The debt level is negligible relative to equity, and the company appears to have ample capacity to service its obligations. However, the gradual rise in total debt from $19.3M in Q4 2024 to $27.0M in Q2 2026, as reported, may indicate a strategic shift toward modest leverage. Given the asset-light model and strong cash position, this is not a concern, but investors should watch for any acceleration in borrowing that could signal a change in capital allocation philosophy.
Asset-Light Model with Rising Intangibles
PP&E of $42.0M in Q2 2026 is only 5.9% of total assets, per reported data, underscoring the asset-light nature of the business, while goodwill of $19.9M remains modest but has grown from $11.9M in Q1 2024.
The balance sheet is dominated by current assets, particularly cash and receivables, which is typical for a service-based healthcare administrator. The increase in goodwill, though small in absolute terms, suggests that acquisitions have been part of the growth strategy. The low PP&E intensity implies minimal capital expenditure requirements, which supports the strong free cash flow conversion observed in the cash flow statement.
Retained Earnings Drive Equity Quality
Retained earnings reached $255.1M in Q2 2026, up from $144.3M in Q4 2024, per balance sheet data, indicating that equity growth is primarily funded by accumulated profits rather than external financing.
The steady increase in retained earnings, despite the deceleration in revenue growth, suggests that the company is generating consistent profitability. However, the prior cash flow analysis noted that stock-based compensation exceeded operating income in Q2 2026, which implies that a portion of the equity growth may be attributable to non-cash charges. Investors should adjust for SBC to assess the true economic earnings power.
Strong Liquidity Buffer Despite Cash Dip
Cash and equivalents of $152.6M in Q2 2026, combined with a current ratio of 2.14, per reported figures, provide a solid liquidity cushion, though cash has declined from $162.3M in Q4 2024.
The current ratio remains above 2.0, indicating that short-term obligations are well covered. The decline in cash from Q4 2024 to Q2 2026, as reported, may be partly due to share repurchases and the timing of claims payments. Given the asset-light model and minimal debt, the liquidity position appears adequate to absorb operational shocks, but the loss of a major client could pressure cash flows if working capital dynamics turn unfavorable.
SBC and Client Losses Distort Balance Sheet
Stock-based compensation of $40.2M in Q2 2026 exceeded operating income, per financials, suggesting that reported equity growth is partly driven by non-cash charges, while the loss of a major client may impair future asset growth.
The balance sheet appears healthy on the surface, but the heavy reliance on SBC to fund equity expansion raises questions about the quality of earnings. Additionally, the reported loss of a significant enterprise client could lead to a reduction in receivables and deferred revenue, potentially shrinking the asset base in coming quarters. Investors should monitor the trajectory of goodwill and intangibles for any impairment risk, especially if the client loss leads to a reassessment of future cash flows.